CSIMarket
 


Liminal Biosciences Inc   (LMNL)
Other Ticker:  
 
 

LMNL's Revenue Growth by Quarter and Year

Liminal Biosciences Inc 's Revenue results by quarter and year




LMNL Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.31 0.49 2.54 3.76
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.31 0.49 2.54 3.76



LMNL Revenue fourth quarter 2022 Y/Y Growth Comment
Liminal Biosciences Inc reported fall in Revenue in the fourth quarter 2022 by -37.31% to $ 0.31 millions, from the same quarter in 2021.
Despite modest results in the fourth quarter 2022, contraction in Liminal Biosciences Inc 's Revenue appears to be smaller than Company's recent average decline.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Revenue growth. While Liminal Biosciences Inc ' s Revenue drop of -37.31% ranks overall at the positon no. 3765 in the fourth quarter 2022.




LMNL Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -37.31 % -80.71 % -32.45 % -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   -37.31 % -80.71 % -32.45 % -

Financial Statements
Liminal Biosciences Inc 's fourth quarter 2022 Revenue $ 0.31 millions LMNL's Income Statement
Liminal Biosciences Inc 's fourth quarter 2021 Revenue $ 0.49 millions Quarterly LMNL's Income Statement
New: More LMNL's historic Revenue Growth >>


LMNL Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   -37.31 % -80.71 % -32.45 % -




Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #212
Healthcare Sector #545
Overall #3765

Revenue Y/Y Growth Statistics
High Average Low
-32.36 % -50.2 % -80.62 %
(Dec 31 2020)   (Dec 31 2021)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #212
Healthcare Sector #545
Overall #3765
Revenue Y/Y Growth Statistics
High Average Low
-32.36 % -50.2 % -80.62 %
(Dec 31 2020)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Liminal Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LMNL's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LMNL's IV. Quarter Q/Q Revenue Comment


Liminal Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 0.31 $ 0.00 $ 0.00 $ 0.00 $ 0.49
Y / Y Revenue Growth (TTM) -37.64 % - - - -80.62 %
Year on Year Revenue Growth Overall Ranking # 3222 # 0 # 0 # 0 # 3872
Seqeuential Revenue Change (TTM) -37.64 % - - - -80.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 3222 # 0 # 0 # 0 # 3872




Cumulative Revenue growth Comment
Liminal Biosciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2022, Liminal Biosciences Inc 's annual Revenue drop would be -37.64% year on year to $0 millions.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3222.

Revenue TTM Q/Q Growth Statistics
High Average Low
-32.36 %
-50.2 %
-80.62 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 172
Healthcare Sector # 474
Overall # 3222

Revenue TTM Y/Y Growth Statistics
High Average Low
-32.36 %
-50.2 %
-80.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 172
Sector # 474
S&P 500 # 3222
Cumulative Revenue growth Comment
Liminal Biosciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2022, Liminal Biosciences Inc 's annual Revenue drop would be -37.64% year on year to $0 millions.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3222.

Revenue TTM Q/Q Growth Statistics
High Average Low
-32.36 %
-50.2 %
-80.62 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 172
Healthcare Sector # 474
Overall # 3222

Revenue TTM Y/Y Growth Statistics
High Average Low
-32.36 %
-50.2 %
-80.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 172
Sector # 474
S&P 500 # 3222




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LMNL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for LMNL's Competitors
Revenue Growth for Liminal Biosciences Inc 's Suppliers
Revenue Growth for LMNL's Customers

You may also want to know
LMNL's Annual Growth Rates LMNL's Profitability Ratios LMNL's Asset Turnover Ratio LMNL's Dividend Growth
LMNL's Roe LMNL's Valuation Ratios LMNL's Financial Strength Ratios LMNL's Dividend Payout Ratio
LMNL's Roa LMNL's Inventory Turnover Ratio LMNL's Growth Rates LMNL's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
National Research Corporation-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd -0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc -1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Uphealth Inc -2.20%$ -2.203 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions
Community Health Systems Inc -2.85%$ -2.846 millions
Invitae Corporation-2.91%$ -2.908 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com